Inhibrx Biosciences Inc(INBX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -8.88 | Insider Own | 25.55% | Shs Outstand | 14.7M | Perf Week | -24.15% |
| Market Cap | 1.08B | Forward P/E | - | EPS next Y | 6.09% | Insider Trans | 1.62% | Shs Float | 11.0M | Perf Month | -26.41% |
| Enterprise Value | 1.13B | PEG | - | EPS next Q | -2.45 | Inst Own | 84.77% | Short Float | 31.18% | Perf Quarter | -10.24% |
| Income | -0.14B | P/S | - | EPS this Y | -5.27% | Inst Trans | 19.18% | Short Ratio | 11.62 | Perf Half Y | -43% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 15.68% | ROA | -75.44% | Short Interest | 3.42M | Perf YTD | -6.77% |
| Book/sh | -3.6 | P/C | 8.13 | EPS past 3/5Y | 3.4% - | ROE | -1773.6% | 52W High | -52.57% ($155.29) | Perf Year | -4.41% |
| Cash/sh | 9.06 | P/FCF | - | Sales past 3/5Y | -15.98% - | ROIC | -109.53% | 52W Low | 28.53% ($57.30) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 19.23% | Gross Margin | - | Volatility(W/M) | 14.32% 7.55% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 7.56 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.07 | EPS Q/Q | -26.26% | Profit Margin | - | RSI (14) | 32.25 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.07 | Sales Q/Q | -100% | SMA20 | -18.81% ($90.71) | Beta | 3.84 | Target Price | $266.67 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | -28.42% ($102.89) | Rel Volume | 1.22 | Prev Close | $73.29 |
| Employees | 110 | LT Debt/Eq | - | EPS/Sales Surpr. | -2.63% - | SMA200 | -20.08% ($92.15) | Avg Volume(3M) | 0.29M | Price | $73.65 |
| IPO | 2024/5/29 | Option/Short | Yes/Yes | Trades | 5153 | Volume | 358,799 | Change | 0.49% |
🧬 Inhibrx Biosciences (INBX) is a US-based, clinical-stage biotechnology company. It develops new drug candidates in oncology and immuno-oncology based on a multivalent antibody format, and it holds a protein therapeutics platform that targets death receptors and immune-stimulating targets. Its value is shaped primarily around late-stage clinical data from its core assets.
Over the past 1 year, on the lower side
53% below its 1-year high.
Traded about as much as usual. That is 122% of its average volume.
INBX has weak earning power
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -5.3% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
31.2% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #154 of 594 in the industry
Based on market cap of $1B.
IMTX#151 Immatics N.V $1B PER - 
JANX#152 Janux Therapeutics Inc $1B PER - 
SGP#153 SpyGlass Pharma Inc $1B PER - INBX#154 Inhibrx Biosciences Inc $1B PER - 
MLTX#155 MoonLake Immunotherapeutics $1B PER - 
FAQ
What kind of company is INBX?
INBX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of INBX?
The market cap of INBX is approximately $1.1B, ranking 2,529 within its sector.
What is the 52-week high and low for INBX?
INBX has recorded a 52-week high of $155.29 and a low of $57.30.
